美国食品药品监督管理局指出 Aldeyra Therapeutics 旗下 Reproxalap 新药申请未能证明对干眼症有效

美股速递
Mar 17

美国食品药品监督管理局(FDA)近日表示,Aldeyra Therapeutics Inc 提交的 Reproxalap 新药申请(NDA)在临床试验中未能充分证明其对干眼症的治疗效果。这一结果对该公司核心产品的上市前景构成重大挑战。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10